

ANG1005 Market Potential

• Base & Upside Case Forecast Assumptions Summary (2025) Not including Label Expansion

Key Forecast Assumptions across ANG1005's Indications for recurrent and newly diagnosed Breast Cancers LC Disease

	<u>Base</u>	<u>Upside</u>	
Launch Year	2029	2030	Phase III clinical trial, 30 months (end of 2028) + NDA approval by FDA (end of 2029)
Time to peak	5 years	3 years	
Peak Eligible Patient Population	16,000	25,000	Estimated by calculating the number of newly diagnosed Breast Cancer patients per year in US (320,000) and then applying a cut (5 – 8 %) for LC disease.
Peak ANG1005 Patients	55 %	55 %	Quantitative survey results (Locus Walk Partners) indicate that ANG1005 will capture more than half of recurrent and newly diagnosed LC patients.
Peak Overall Patient Penetration	8,800	13,750	
Cost per cycle of Therapy	5,000 \$	7,000 \$	The proposed pricing for ANG1005 of 5,000 \$ per cycle (similar to Temodar™) was less than expected by several interviewees (> 7,000 \$ / month radiotherapy)
Median Cycles/Length of Therapy	8 cycles	11 cycles	Base Case Forecast = OS > 6 months (1 Cycle = 3 weeks) Upside Case Forecast = OS > 8 months (1 Cycle = 3 weeks)
Peak Sales	350 M \$	1,050 M \$	
RoW Gross up (% of US Net Sales)	EU 78 % Japan 22 % RoW 22 %		Base on Navigant Consulting Group, ANG1005 market analysis for secondary brain cancer metastases.

The global paclitaxel injection market size was estimated at USD 6.26 billion in 2024 and is anticipated to reach around USD 17.52 billion by 2034, expanding at a CAGR of 12.30% from 2025 to 2034.